	US 12,233,073 B2
	Skin care formulations and skin cancer treatment
Ann M. Bode, Cannon Falls, MN (US); Zigang Dong, Austin, MN (US); and Eunmiri Roh, Austin, MN (US)
Assigned to Regents of the University of Minnesota, Minneapolis, MN (US)
Appl. No. 16/620,382
Filed by Regents of the University of Minnesota, Minneapolis, MN (US)
PCT Filed Jun. 8, 2018, PCT No. PCT/US2018/036720 § 371(c)(1), (2) Date Dec. 6, 2019, PCT Pub. No. WO2018/227129, PCT Pub. Date Dec. 13, 2018.
Claims priority of provisional application 62/517,257, filed on Jun. 9, 2017.
Claims priority of provisional application 62/517,319, filed on Jun. 9, 2017.
Prior Publication US 2020/0179404 A1, Jun. 11, 2020
Int. Cl. A61K 35/04 (2006.01); A61K 9/00 (2006.01); A61K 31/573 (2006.01); A61K 31/58 (2006.01); A61P 35/04 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/573 (2013.01) [A61K 9/0014 (2013.01); A61K 31/58 (2013.01); A61P 35/04 (2018.01); A61K 45/06 (2013.01)]

20 Claims

1. A method for treating a skin condition, the method comprising administering a composition comprising a therapeutically effective amount of a p53-related protein kinase (PRPK) inhibitor to a patient having skin cancer or having a high risk of developing skin cancer, wherein the composition comprises 0.1% to 1% (weight/volume) of the PRPK inhibitor, and wherein the PRPK inhibitor comprises rocuronium bromide or analogs thereof.